Baltimore Convention Center

Projection and Baltimore Convention Center Renew Partnership, Expanding Services

Retrieved on: 
金曜日, 5月 10, 2024
Entertainment, Networks, Events, Concerts, Other Travel, Technology, Destinations, Commercial Building & Real Estate, Travel, Construction & Property, Other Entertainment, Audio, Video, Building Systems, Other Technology, Partnership, Employment, Baltimore Convention Center, Corporation, Sound, Projection, Growth, Multimedia, Rail transport

Projection, a leading event technology service provider, is delighted to announce the renewal and expansion of its partnership with the Baltimore Convention Center through 2031.

Key Points: 
  • Projection, a leading event technology service provider, is delighted to announce the renewal and expansion of its partnership with the Baltimore Convention Center through 2031.
  • As part of this continued collaboration, Projection will maintain its position as the preferred in-house audiovisual services provider while introducing exclusive rigging services to enhance the event experience for clients at the Center.
  • View the full release here: https://www.businesswire.com/news/home/20240510074485/en/
    Larry Taylor, Corporate Vice President for the In-House Division at Projection, expressed enthusiasm about the renewed collaboration: "We are excited to build upon our strong relationship with the Baltimore Convention Center and provide 'The Projection Difference' to our mutual clients.
  • About the Baltimore Convention Center:
    The Baltimore Convention Center, located in the vibrant Inner Harbor area, is one of the East Coast's premier event venues.

Capsida Biotherapeutics to Present Preclinical Data for Parkinson's Disease Associated with GBA Mutations Showing High Levels of GCase Enzyme Supplementation Following IV Administration

Retrieved on: 
金曜日, 5月 10, 2024
Traffic barrier, Patient, Cell, PD, Parkinson's disease, Baltimore Convention Center, Liver, Dorsal root ganglion, Disease, DSM-IV codes, Gene, Neuron, Cerebrospinal fluid, Brain, Society, Annual general meeting, GBA, Potential

THOUSAND OAKS, Calif., May 10, 2024 /PRNewswire/ -- Capsida Biotherapeutics ("Capsida") today announced new preclinical data that demonstrate the potential of its next-generation intravenously (IV) administered gene therapy candidate, CAP-003, to safely and effectively treat Parkinson's disease (PD) associated with GBA mutations (PD-GBA). Collectively, the findings strongly support the best-in-class profile of CAP-003 and Capsida's plans to advance the therapy into clinical trials in the first half of 2025.

Key Points: 
  • Mutations in GBA, the gene expressing the GCase enzyme, are the most common genetic risk factor for PD.
  • Other treatments for PD-GBA have been limited by their inability to cross the blood-brain barrier and supplement GCase enzyme activity in sufficient quantities to impact the disease.
  • Capsida's wholly owned novel gene therapy offers the potential to supplement the GCase enzyme with a single IV infusion, enabling long-term disease modification and substantially slowing disease progression.
  • "Our novel wholly owned PD-GBA gene therapy demonstrates the potential to provide long-term significant decrease in disease progression safely with a single IV infusion," said Capsida CEO Peter Anastasiou.

Creyon Bio to Present Clinical Data on Rapid AI-Enabled Engineering of Oligonucleotide-Based Medicines at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

Retrieved on: 
火曜日, 5月 7, 2024
FDA, Brain, University, Rady, Seizure, Hope, Safety, AI, Asos, Health, Partnership, Trial of the century, Cell, Artificial intelligence, U.S. FDA, Entrepreneurship, Disease, Engineering, Attention, Family, Gene, Society, MRI, Locked nucleic acid, Pediatrics, TNPO2, CSF, Central nervous system, Drug development, GMP, DSM-IV codes, Annual general meeting, Associate, Behavior, LNA, Cerebrospinal fluid, SAN, Baltimore Convention Center, OBM, Pharmaceutical industry

SAN DIEGO and RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Creyon Bio, Inc. ("Creyon"), a clinical stage drug development company that engineers Oligonucleotide-Based Medicines (OBMs) with industry-leading efficiency creating novel, best-in-class gene-centric medicines to treat rare and common diseases, today announced encouraging clinical data highlighting the use of its custom designed data set paired with artificial intelligence (AI) to rapidly engineer an investigational antisense oligonucleotide (ASO) therapy. Within one year of project initiation in partnership with The TNPO2 Foundation, Creyon developed a novel allele-selective Locked Nucleic Acid (LNA) treatment candidate for an ultra-rare and severe neurological disease caused by a single nucleotide variant in the Transportin-2 (TNPO2) receptor, and an investigator-initiated clinical trial received approval to dose a patient. Initial data from this trial demonstrate that the investigational treatment successfully reduced seizures, restored developmental milestones, and was well-tolerated over nine months. Creyon will share these results during an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting in Baltimore on Friday, May 10, 2024, between 5:15-5:30 p.m. EDT in Room 307-308 of the Baltimore Convention Center.

Key Points: 
  • Initial data from this trial demonstrate that the investigational treatment successfully reduced seizures, restored developmental milestones, and was well-tolerated over nine months.
  • Creyon will share these results during an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting in Baltimore on Friday, May 10, 2024, between 5:15-5:30 p.m. EDT in Room 307-308 of the Baltimore Convention Center.
  • “We developed predictive models that guide our molecular engineering from the outset and help mitigate potential safety concerns.
  • “Inflammatory reactions to oligonucleotide therapies have caused serious adverse reactions in other early clinical-stage therapies delivered directly to the central nervous system.

Capsida Biotherapeutics Presents New Preclinical Evidence Indicating Novel First-in-Class IV-Administered Gene Therapy Effectively Treats Genetic Epilepsy Due to STXBP1 Mutations

Retrieved on: 
火曜日, 5月 7, 2024
Doctor of Philosophy, Brain, Traffic barrier, Mouse, Phenotype, Poster, MD, Model, Cell, Deficit spending, Associate professor, STXBP1, AAV, DSM-IV codes, Vivisection, Genetics, Disease, Patient, Liver, Baylor College of Medicine, Society, Gene, Treatment, Neurology, Seizure, Gene expression, Neuron, Annual general meeting, Texas Children's Hospital, Baylor University, Baltimore Convention Center, Vaccine

THOUSAND OAKS, Calif., May 7, 2024 /PRNewswire/ -- Capsida Biotherapeutics ("Capsida") today announced new preclinical data supporting the potential of Capsida's gene therapy candidate, CAP-002, to achieve levels of gene supplementation necessary to correct neurological phenotypes associated with genetic epilepsy due to syntaxin-binding protein 1 (STXBP1) mutations.

Key Points: 
  • Gene therapy for genetic epilepsy due to STXBP1 mutations has not been previously possible because earlier generation adeno-associated viruses (AAVs) or wild-type AAVs could not achieve the level of widespread neuronal transduction required to modify the disease.
  • CAP-002 is a first-in-class next-generation intravenous (IV)-administered gene therapy that achieves brain-wide neuronal expression while simultaneously detargeting the liver.
  • Capsida's wholly owned program is currently in IND-enabling studies and is expected to enter the clinic in the first half of 2025.
  • This level of gene expression raises neuronal STXBP1 protein to levels comparable to those that reversed disease phenotype in the mouse model.

Ring Therapeutics Announces Presentations at the 27th Annual American Society of Gene and Cell Therapy

Retrieved on: 
月曜日, 4月 22, 2024
Tropism, Therapy, Flagship Pioneering, Baltimore Convention Center, Gene, Society, Cell, Conference, Vaccine

CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize genetic medicines with its commensal virome platform, today announced an oral presentation and two poster presentations at the 27th Annual American Society of Gene & Cell Therapy (ASGCT) Conference, to be held in Baltimore, Maryland from May 7 – 11, 2024. These presentations showcase the immense promise of a new class of viral vectors from Ring’s Anellogy™ platform to overcome some of the largest barriers associated with delivery of current genetic medicines including redosability and tissue tropism.

Key Points: 
  • CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Ring Therapeutics , a life sciences company founded by Flagship Pioneering to revolutionize genetic medicines with its commensal virome platform, today announced an oral presentation and two poster presentations at the 27th Annual American Society of Gene & Cell Therapy (ASGCT) Conference, to be held in Baltimore, Maryland from May 7 – 11, 2024.
  • These presentations showcase the immense promise of a new class of viral vectors from Ring’s Anellogy™ platform to overcome some of the largest barriers associated with delivery of current genetic medicines including redosability and tissue tropism.
  • Session Title and Location: Emerging Viral Vectors – Ballroom 4, Baltimore Convention Center

Beyond Van Gogh and Beyond Monet: The Immersive Experiences to Open at the Baltimore Convention Center on July 5

Retrieved on: 
火曜日, 4月 30, 2024
General Entertainment, Arts, Museums, Entertainment, Events, Concerts, Sale, Dream, Emotion, Poppies, Painting, Water Lilies (Monet series), Baltimore Convention Center, Tourism

Producer Paquin Entertainment Group announced today that Beyond Van Gogh: The Immersive Experience and Beyond Monet: The Immersive Experience will open on July 5, 2024 at the Baltimore Convention Center.

Key Points: 
  • Producer Paquin Entertainment Group announced today that Beyond Van Gogh: The Immersive Experience and Beyond Monet: The Immersive Experience will open on July 5, 2024 at the Baltimore Convention Center.
  • Having sold over seven million tickets worldwide, audiences can enjoy these two blockbuster immersive events individually or together as one combo ticket.
  • Pre-sales begin today with tickets going on sale to the public on Friday, May 3 at 9:00 a.m. at beyondexhibitions.com .
  • “Through cutting edge technology, these immersive experiences are redefining what art means to people,” says Paquin Entertainment Group’s President of Exhibitions and Theatrical, Justin Paquin.

Vesigen to Present New Preclinical Data on Engineered ARMMs Technology at 2024 ASGCT Annual Meeting

Retrieved on: 
月曜日, 4月 22, 2024
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, RNA, Cell, Gene, Society, Annual general meeting, Therapy, Baltimore Convention Center, Vaccine

Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today announced that the Company will be presenting 10 posters sharing new preclinical data from its engineered ARMMs platform at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting .

Key Points: 
  • Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today announced that the Company will be presenting 10 posters sharing new preclinical data from its engineered ARMMs platform at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting .
  • Vesigen’s delivery technology has been shown to be non-immunogenic and is re-dosable.
  • Vesigen will be presenting new preclinical data demonstrating successful biodistribution of its ARMMs in non-human primates (NHPs).
  • The team will also be sharing data on its new targeted ARMMs technology, demonstrating the ability to deliver to otherwise hard-to-reach cell types.

Scribe Therapeutics to Present on Advances in CRISPR Genome and Epigenome Editing at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Retrieved on: 
月曜日, 4月 22, 2024
Stem Cells, Biotechnology, Health, General Health, Pharmaceutical, Other Science, Research, Infectious Diseases, Genetics, Science, Clinical Trials, XE, CRISPR, Epigenetics, Cell, Gene, Society, Annual general meeting, Baltimore Convention Center

Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced its participation in the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place at the Baltimore Convention Center in Baltimore, MD, and virtually from May 7-11, 2024.

Key Points: 
  • Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced its participation in the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place at the Baltimore Convention Center in Baltimore, MD, and virtually from May 7-11, 2024.
  • Scribe will deliver two oral presentations and one poster presentation showcasing the latest developments in its CRISPR X-Editor (XE) and Epigenetic Long-Term X-Repressors (ELXR) technologies enabled by its CRISPR by Design™ approach.
  • The company’s presentations will include data demonstrating the potent editing activity of XE in non-human primates, the potential for XE to address P23H.RHO-related autosomal dominant retinitis pigmentosa (adRP), and the comprehensive engineering approach to creating highly potent ELXRs.

CompTIA supports Department of Defense efforts to strengthen cyber knowledge and skills

Retrieved on: 
火曜日, 4月 23, 2024
Information, Certification, Policy, CompTIA, ISO, Information technology, Military personnel, Workforce, AFCEA, American National Standards Institute, ANSI, Baltimore Convention Center, Defense

DOWNERS GROVE, Ill., April 23, 2024 /PRNewswire/ -- CompTIA, the world's leading information technology (IT) certification and training body, announced today that eight of its certifications are included in U.S. Department of Defense efforts to create, qualify and upskill a more diverse workforce to protect the nation's interests, information and infrastructure.

Key Points: 
  • The Cyber Workforce Qualification Program, which includes U.S. Department of Defense Manual 8140.03 (DoDM 8140.03), modernizes DoD talent management, allowing for more targeted and flexible approaches and options to manage and achieve a qualified cyber workforce in IT, cybersecurity, cyber effects, cyber intelligence and cyber enablers.
  • The eight CompTIA certifications [1] approved for DoDM 8140.03 cover 31 different work roles within the DoD cyber workforce.
  • These job roles range from technical support and network operations specialists to cyber defense forensic analysts, cyber policy and strategy planners and information systems security developers and managers.
  • CompTIA certifications validate essential skills through performance-based exams that assess an individual's ability to solve problems in real-world settings.

Epic Bio Announces Robust Slate of Presentations at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

Retrieved on: 
火曜日, 4月 9, 2024
Poster, SAN, Cell, Abstract, Baltimore Convention Center, Gene, FSHD, Ballroom, Society, Convention, Dentistry

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Epic Bio , a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced the acceptance of six abstracts, three oral presentations, and three poster presentations at the upcoming Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 7-11, 2024, in Baltimore, Maryland.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Epic Bio , a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced the acceptance of six abstracts, three oral presentations, and three poster presentations at the upcoming Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 7-11, 2024, in Baltimore, Maryland.
  • Location: Baltimore at the Baltimore Convention Center, Ballroom 1, Baltimore, Maryland
    Location: Baltimore at the Baltimore Convention Center, Ballroom III, Baltimore, Maryland
    Location: Baltimore at the Baltimore Convention Center, Ballroom III, Baltimore, Maryland
    Location: Baltimore at the Baltimore Convention Center, Exhibit Hall, Baltimore, Maryland
    Location: Baltimore at the Baltimore Convention Center, Exhibit Hall, Baltimore, Maryland